about
Modeling ligand recognition at the P2Y12 receptor in light of X-ray structural information.Caffeine acts through neuronal adenosine A2A receptors to prevent mood and memory dysfunction triggered by chronic stress.Crystal structure of NTPDase2 in complex with the sulfoanthraquinone inhibitor PSB-071Dopaminergic modulation of effort-related choice behavior as assessed by a progressive ratio chow feeding choice task: pharmacological studies and the role of individual differencesCardiac myocyte-secreted cAMP exerts paracrine action via adenosine receptor activation.Combinatorial synthesis of anilinoanthraquinone derivatives and evaluation as non-nucleotide-derived P2Y2 receptor antagonists.Central P2Y12 receptor blockade alleviates inflammatory and neuropathic pain and cytokine production in rodents.The VMAT-2 inhibitor tetrabenazine affects effort-related decision making in a progressive ratio/chow feeding choice task: reversal with antidepressant drugs.Fluorescence polarization immunoassays for monitoring nucleoside triphosphate diphosphohydrolase (NTPDase) activity.Effort-related motivational effects of the pro-inflammatory cytokine interleukin 1-beta: studies with the concurrent fixed ratio 5/ chow feeding choice task.P2Y12 Receptor Localizes in the Renal Collecting Duct and Its Blockade Augments Arginine Vasopressin Action and Alleviates Nephrogenic Diabetes Insipidus.Stimulant effects of adenosine antagonists on operant behavior: differential actions of selective A2A and A1 antagonists.The caffeine-binding adenosine A2A receptor induces age-like HPA-axis dysfunction by targeting glucocorticoid receptor function.Effort-related motivational effects of the VMAT-2 inhibitor tetrabenazine: implications for animal models of the motivational symptoms of depression.Ethanol and Caffeine Effects on Social Interaction and Recognition in Mice: Involvement of Adenosine A2A and A1 Receptors.Allosteric modulators of rhodopsin-like G protein-coupled receptors: opportunities in drug development.Ecto-nucleotidase inhibitors: recent developments in drug discovery.Dual target strategy: combining distinct non-dopaminergic treatments reduces neuronal cell loss and synergistically modulates L-DOPA-induced rotational behavior in a rodent model of Parkinson's disease.Date Palm Tree (Phoenix dactylifera L.): Natural Products and Therapeutic Options.Effort-related motivational effects of the pro-inflammatory cytokine interleukin-6: pharmacological and neurochemical characterization.Inhibitors for the bacterial ectonucleotidase Lp1NTPDase from Legionella pneumophila.A2A adenosine receptor deletion is protective in a mouse model of Tauopathy.Syntheses of 2-substituted 1-amino-4-bromoanthraquinones (bromaminic acid analogues) - precursors for dyes and drugs.Competitive mode and site of interaction of ticagrelor at the human platelet P2Y12 -receptor.Discovery of potent competitive antagonists and positive modulators of the P2X2 receptor.Structure-activity relationships of anthraquinone derivatives derived from bromaminic acid as inhibitors of ectonucleoside triphosphate diphosphohydrolases (E-NTPDases).Synthesis of alkyl- and aryl-amino-substituted anthraquinone derivatives by microwave-assisted copper(0)-catalyzed Ullmann coupling reactions.Interaction of new, very potent non-nucleotide antagonists with Arg256 of the human platelet P2Y12 receptor.Adenosine A(2A) receptor blockade reverts hippocampal stress-induced deficits and restores corticosterone circadian oscillation.L-DOPA disrupts adenosine A(2A)-cannabinoid CB(1)-dopamine D(2) receptor heteromer cross-talk in the striatum of hemiparkinsonian rats: biochemical and behavioral studies.High-affinity, non-nucleotide-derived competitive antagonists of platelet P2Y12 receptors.Adenosine receptor antagonists including caffeine alter fetal brain development in mice.Convergent synthesis of the potent P2Y receptor antagonist MG 50-3-1 based on a regioselective Ullmann coupling reaction.Treatment with A2A receptor antagonist KW6002 and caffeine intake regulate microglia reactivity and protect retina against transient ischemic damage.Molecular Recognition of Agonists and Antagonists by the Nucleotide-Activated G Protein-Coupled P2Y2 Receptor.Effect of subtype-selective adenosine receptor antagonists on basal or haloperidol-regulated striatal function: studies of exploratory locomotion and c-Fos immunoreactivity in outbred and A(2A)R KO mice.The vesicular monoamine transporter (VMAT-2) inhibitor tetrabenazine induces tremulous jaw movements in rodents: implications for pharmacological models of parkinsonian tremor.The novel adenosine A(2A) antagonist prodrug MSX-4 is effective in animal models related to motivational and motor functions.Adenosine A2A receptor antagonism and genetic deletion attenuate the effects of dopamine D2 antagonism on effort-based decision making in mice.Development of Potent and Selective Antagonists for the UTP-Activated P2Y4 Receptor.
P50
Q27316009-90389C50-9393-4600-8C39-C0C7952C6579Q27324798-15AFB40D-6728-4B87-BA88-7571186BF261Q27688970-3A88C58E-B14D-4C1E-B26D-CB9F1C3D2EA3Q28484509-670CE1E6-62A7-4279-8845-C39514DAA068Q30615893-322FC309-9E6E-402F-89A3-6045C5049FDDQ33305758-18974323-AE86-4708-A702-D0819E46B852Q34104414-FD57B287-882B-4E09-BAE8-B7F2E27EE48DQ35189617-DD759DAB-22D2-4238-AA9D-4407A2541EEDQ35394974-4888EED1-54A8-41F4-A4D6-DE7936CA2BE1Q35746360-7B4AB56A-B5B3-439B-814C-D603B6CC070EQ36314883-8EBA4DD8-3CE9-4C8F-8715-D030C105BDF4Q36466181-DEA42BA7-51D6-4FAA-961A-78A5D190FE17Q37166542-55DAB6EB-AF8F-4C0E-A1C1-AC7DF971A1B0Q37362447-A84B5A24-0D9C-4F30-8123-7E84C330710BQ37385936-62B4DF22-05FA-493D-B47D-A574E3913800Q38021236-4AD60290-3584-4729-A0D2-DDDB0F46C8FEQ38360862-92F94F31-5C4E-4848-AE02-95DF829C9DE7Q39008496-383A3660-4A3A-499B-AD7A-D0ED57B8CE5DQ39355455-13854E32-3523-401E-975C-E3A6E9C170E8Q40093821-6ACEDCDA-24A8-42FC-83B6-A3AAE9E3629AQ40576735-27AE99BB-281C-4C16-97D2-7CF08818E847Q41755392-3CAA99CD-EC54-4D1D-91B2-660924D65039Q41952614-B9FE0CC7-ABC0-4D81-B96E-BEC94638857AQ42704294-07016C11-C0E7-4912-A7E3-92867C56597BQ42761493-3E204055-BF5E-4E6E-B461-089B8BEB4C28Q42957025-A0CD7238-96E2-4DC3-A8AB-873FA10054BCQ43079085-2DA31B65-A89E-422C-85E9-2598796EEAB3Q43290040-794767B0-EC67-451B-A124-84BEAAE9A9CBQ44390057-F6F61C1F-C9C9-4642-8848-D9071031EBBBQ45228276-4DF96E61-99A9-457D-96CF-1AF2A1D474BDQ46000448-DC6D885F-5CFB-485D-B7E2-A8B340A8FE25Q46127416-49E27CDF-6EE0-4AF9-A6CC-4F062BCC1020Q46782450-9F3FAD38-418E-4D73-BE1A-CB6A848F0CC5Q47387315-3C8FD655-C653-4131-8CBA-E874A2611D15Q47761844-7CA417CE-BB29-4FD1-BB30-44ABD1D33A01Q47900319-26256E74-03E4-40EF-AD43-EFBE4BA2814BQ47981305-4AFDD3AC-2737-4013-903A-F5404DD67017Q47981413-3012AA4C-50A7-454A-84ED-6DA89697E6CEQ48014966-784AA78C-AC2E-405C-A4A0-AA91B8034E0DQ48110307-8E478BD1-431B-43E2-A5CA-0EB731A9A0FA
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Y Baqi
@ast
Y Baqi
@en
Y Baqi
@es
Y Baqi
@nl
Y Baqi
@sl
type
label
Y Baqi
@ast
Y Baqi
@en
Y Baqi
@es
Y Baqi
@nl
Y Baqi
@sl
altLabel
Y Baqi
@en
Younis N H Baqi
@en
prefLabel
Y Baqi
@ast
Y Baqi
@en
Y Baqi
@es
Y Baqi
@nl
Y Baqi
@sl
P1053
I-8240-2016
P106
P1153
15049201800
P1960
KJEfqhMAAAAJ
P2038
Younis_Baqi
P2798
P31
P3829
P3835
younis-baqi
P496
0000-0002-9659-8419
P569
2000-01-01T00:00:00Z